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Oxidative stress and mitochondrial dysfunction play a crucial role in the pathophysiology
of muscular dystrophies. We previously reported that the mitochondrial enzyme
monoamine oxidase (MAO) is a relevant source of reactive oxygen species (ROS)
not only in murine models of muscular dystrophy, in which it directly contributes to
contractile impairment, but also in muscle cells from collagen VI-deficient patients. Here,
we now assessed the efficacy of a novel MAO-B inhibitor, safinamide, using in vivo
and in vitro models of Duchenne muscular dystrophy (DMD). Specifically, we found
that administration of safinamide in 3-month-old mdx mice reduced myofiber damage
and oxidative stress and improved muscle functionality. In vitro studies with myogenic
cultures from mdx mice and DMD patients showed that even cultured dystrophic
myoblasts were more susceptible to oxidative stress than matching cells from healthy
donors. Indeed, upon exposure to the MAO substrate tyramine or to hydrogen peroxide,
DMD muscle cells displayed a rise in ROS levels and a consequent mitochondrial
depolarization. Remarkably, both phenotypes normalized when cultures were treated
with safinamide. Given that safinamide is already in clinical use for neurological disorders,
our findings could pave the way toward a promising translation into clinical trials for DMD
patients as a classic case of drug repurposing.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is the one of the most common and severe forms of
inherited muscular dystrophies. Despite improvements in palliative and support care, it is still
invariably lethal because of cardiac-respiratory failure (Davies and Nowak, 2006; Shin et al., 2013),
usually between the second and third decade of life. The only clinically available therapies rely on
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steroid anti-inflammatory molecules, although a number of
other drugs are presently in clinical trials (Rosenberg et al.,
2015; Guiraud and Davies, 2017). Two genetic-based drugs have
recently been approved for clinical use (Fairclough et al., 2013),
but they are aimed at patients bearing defined mutations and
their efficacy is still marginal.
Even though the genetic bases of most inherited muscular
dystrophies have been characterized, the underlying pathogenic
mechanisms remain somewhat elusive. Mitochondrial
dysfunction has been shown to play a key role (Irwin et al., 2003;
Angelin et al., 2007; Merlini et al., 2008; Millay et al., 2008; Palma
et al., 2009; Menazza et al., 2010; Sorato et al., 2014; Chartier et al.,
2015), although in the case of DMD, the mechanisms connecting
lack of dystrophin, a sub-sarcolemmal protein, to mitochondrial
alterations are unclear. A likely candidate is oxidative stress,
as highlighted by several studies (Disatnik et al., 1998; Rando,
2002; Tidball and Wehling-Henricks, 2007; Williams and Allen,
2007; Whitehead et al., 2008; Lawler, 2011; Canton et al., 2014).
In this regard, we previously demonstrated that monoamine
oxidase (MAO), a mitochondrial enzyme widely studied in
the central nervous system, is an essential source of reactive
oxygen species (ROS) in dystrophic muscles (Menazza et al.,
2010). The two isoforms of MAO, A and B, located in the outer
mitochondrial membrane, catalyze the oxidative deamination
of biogenic amines generating aldehydes, ammonia, and H2O2,
which are removed by enzymatic scavengers in physiological
conditions (Youdim et al., 2006). We have already reported
that MAO expression and activity increase in muscles from two
murine models of muscular dystrophies, mdx for DMD and
Col6a1−/− mice for collagen VI-related myopathies (Menazza
et al., 2010). This results in excessive levels of H2O2, which
in turn alters the redox homeostasis and causes myofibrillar
protein oxidation, hampering contractile function. Importantly,
treatment with pargyline, an inhibitor of both MAO isoforms,
reduced oxidation of tropomyosin and led to improvements
in the phenotype of dystrophic mice (Menazza et al., 2010).
The involvement of MAO in muscular dystrophy has also been
seen in in vitro myoblasts cultures obtained from patients with
collagen VI myopathies (Sorato et al., 2014). Specifically, in
these cells, pargyline treatment reduced ROS accumulation and
mitochondrial dysfunction, while normalizing the occurrence
of apoptosis. These findings proved that MAO-dependent ROS
accumulation is directly linked to mitochondrial dysfunction and
suggested that it is upstream of the opening of the permeability
transition pore (Sorato et al., 2014).
In our previous researches, pargyline was chosen as a “proof-
of-principle” molecule in assessing MAO role in muscular
dystrophy, thanks to its strong and irreversible inhibitory effect.
However, its use in patients is hampered by significant side
effects and its clinical use has been discontinued in favor of
different, well-tolerated MAO inhibitors that are now commonly
used in clinics for neurological disorders (Youdim et al., 2006).
Among these, inhibitors specific for MAO-B, which are mainly
used for treatment of Parkinson disease, have the advantage of
not causing the severe side effects seen with drugs inhibiting
MAO-A. In the present study, we investigate for the first time
the specific role of MAO-B in cultured muscle cells from DMD
patients and in skeletal muscles of mdx mice, by using the
novel pharmacological MAO-B inhibitor safinamide. Our data
demonstrate that accumulation of ROS related to MAO-B activity
not only plays a crucial role in the loss of cell viability and
contractile impairment of dystrophic skeletal muscles but also
in the mitochondrial dysfunction occurring in DMD myogenic
cultures, thereby pointing at safinamide as a promising candidate
for DMD therapy.
MATERIALS AND METHODS
Chemicals
Safinamide was kindly provided by Zambon SpA (batch
14A03C0483) and dissolved in water or phosphate-buffered
saline (PBS). Unless otherwise stated, all chemicals used were
purchased from Sigma-Aldrich.
Mice and Safinamide in vivo Treatments
Wild-type C57BL/10ScSnJ and mdx mice (C57BL/10ScSn-
Dmdmdx/J) were obtained from Charles River and Jackson
Laboratories, respectively, and were bred and maintained in the
animal facility of the Venetian Institute for Molecular Medicine
(VIMM). Safinamide (20 or 40 mg/kg/day), prednisolone
(2 mg/kg/day), or vehicle (PBS) were administered by daily
intra peritoneal injection for 7 or 30 days in 3-month-old mdx
and C57BL/10ScSn male mice. The doses of safinamide were
chosen based on preliminary data obtained by ZambonGroup.
At the end of the treatment, animals were first analyzed for
force measurements and then sacrificed for muscle harvesting.
Collected samples were then stored in liquid nitrogen until
use. All in vivo experiments were approved by the Institutional
Animal Care and Use Committee of the University of Padova.
Muscle Functional Assessment
Muscle function in vivo was assessed for the gastrocnemius
muscle, as described previously (Blaauw et al., 2008). Briefly, mice
were anesthetized, and electrodes were placed on either side of the
sciatic nerve, while the common peroneal nerve was cut. Muscle
torque production was measured using a lever system (Aurora
Scientific 305B). A lever arm of 2.1 mm was used for all groups, as
no major differences in body weight between various groups was
observed. Eccentric contractions were performed by moving the
foot backward at a velocity of 40 mm/s while the gastrocnemius
was stimulated with a frequency sufficient to induce full tetanic
fusion (100 Hz). Contractions were repeated once every 20 s to
avoid inducing fatigue.
Analyses of Oxidation State in Skeletal
Muscles
Dihydroethidium Staining
Dihydroethidium (DHE) is oxidized by ROS, forming ethidium
bromide, which emits red fluorescence when intercalates with
DNA (Benov et al., 1998). Gastrocnemius cryosections (10 µm
thick) were incubated with 5 µM DHE (Sigma) for 30 min
at 37◦C in degassed PBS, washed twice in PBS, mounted and
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visualized using an inverted microscope Leica DMI6000B, as
previously described (Menazza et al., 2010). Data were acquired
and analyzed using Metamorph software (Universal Imaging).
Tropomyosin Oxidation
Assessment of tropomyosin oxidation was carried out by western
blot analyses. Protein extracts were prepared homogenizing tissue
samples in ice-cold PBS, pH 7.2 containing a protease inhibitor
mix, subjected to PAGE, and then transferred onto nitrocellulose,
as detailed in (Canton et al., 2006). Immunoblotting were then
stained with an anti-tropomyosin antibody (anti-Tm, CH1 clone,
Sigma-Aldrich). In anti-Tm immunoblots, the presence of high-
molecular-mass bands was attributed to the oxidation-driven
formation of disulphide cross-bridges (DCB), by comparing
electrophoreses carried out in the absence or in the presence of
β-mercaptoethanol, as previously described (Canton et al., 2006).
Quantitation of Tm oxidation was performed by densitometric
analysis of the bands obtained under non-reducing conditions,
using the ImageJ software1. DCB density was normalized to the
actin density in Red Ponceau, to account for differences in sample
loading. Data were expressed as percentage of DCB relative to
vehicle-treated mdx mice.
Pathological Markers
Cross-sections (7 µm thick) were prepared and processed for
hematoxylin and eosin (H&E) staining. For the morphometric
analysis of myofiber CSAs, we counted between 5000 and 6000
gastrocnemius fibers per mouse, by means of ImageJ software.
Images were acquired from least three non-sequential sections
from each muscle. The same images were also analyzed to assess
the percentage of centrally nucleated fibers.
Membrane permeability of skeletal fibers, used as a marker
of necrosis, was visualized by immunohistochemical staining
with IgG (Blaauw et al., 2008). Cryosections (10 µm thick)
were incubated with anti-mouse fluorescein isothiocyanate-
conjugated IgG, washed twice with PBS, mounted, and visualized
with an Olympus IMT-2 inverted microscope as previously
described (Menazza et al., 2010) using excitation/emission cubes
of 488/525+ 25 nm bandpass.
Creatine Kinase Assay
Serum creatine kinase (CK) was performed using a dedicated
assay kit (BioAssay Systems, Hayward, CA, United States),
following manufacturer’s instructions. Blood was collected by
cardiac puncture from animals anesthetized with pentobarbital.
Immediately after bleeding, animals were killed by cervical
dislocation. Sera were separated by centrifugation at 300 × g for
5 min and were stored at−80◦C until use.
Myogenic Cell Cultures
Murine myoblasts were isolated from the diaphragm of 2- to 3-
month-old mdx mice with a standard enzymatic (Collagenase I)
digestion/serial pre-plating technique.
Primary DMD and control myoblasts were kindly provided
by the “Telethon Bio-Bank” (“Besta” Neurology Institute, Milan,
1https://imagej.net/ImageJ1
Italy) and by the Neuroscience Department of the University
of Padova. Primary myoblasts (both murine and human)
were expanded in gelatin-coated dishes with proliferation
medium: F12 medium (Invitrogen), 20% fetal bovine serum
(FBS, Invitrogen), 5 ng/mL FGFb (Immunotools), penicillin–
streptomycin mix (Invitrogen). Myoblast differentiation in
myotubes was induced by switching confluent cultures to
differentiate medium: high-glucose DMEM, 2% horse serum
(Invitrogen), 10 mg/mL insulin (from bovine pancreas,
Sigma-Aldrich), penicillin–streptomycin mix (Invitrogen).
Immortalized human myoblasts, kindly provided by the Institut
de Myologie (Pitié-Salpétrière Hospital, Paris, France), had been
obtained as described in Mamchaoui et al. (2011) by double
transduction with hTERT and cdk4. Cells were expanded in
proliferation medium: M199-DMEM mix (1:4 ratio), 20% FBS,
Fétuin 25 µg/ml (Invitrogen), hEGF 5 ng/ml (Immunotools),
Insulin 5 µg/ml (Sigma-Aldrich), Dexamethasone 0.2 µg/ml
(Sigma-Aldrich), 20% FBS, penicillin–streptomycin mix
(Invitrogen). For differentiation, confluent cultures were exposed
to a serum-free medium comprising DMEM (Invitrogen), insulin
10 µg/ml (Sigma-Aldrich), and penicillin–streptomycin mix
(Invitrogen) for 5–7 days.
ROS Detection
Reactive oxygen species were detected using the fluorescent
probe MitoTracker Red CM-H2XRos (MTR, Molecular Probes,
Eugene, OR, United States). Myoblasts were seeded onto 24-mm
diameter gelatine-coated glass coverslips placed in six-well plates,
and then kept for 2 days in the appropriate growth medium.
For myotubes, upon reaching confluence cells were switched
to the appropriate differentiation medium and kept in culture
for 6–8 days. For the experiments, cells were rinsed once and
then incubated with either MAO inhibitor pargyline (100 µM,
determined from previous experiments) or 1 µM safinamide
for 20 min in serum-free media, followed by the addition of
H2O2 (100 µM) or tyramine (100 µM) for 45 min. Working
concentration of safinamide was determined in preliminary
experiments using a 0.5–4 µM concentration range, which
indicated 1 µM as the lowest dose with highest response (data
not shown). Finally, myoblasts were loaded with MTR (20 nM)
for 15 min. All the steps were carried out at 37◦C with 5% CO2.
Myoblasts were then washed twice, and the chambered coverslips
were transferred to a Leica DMI6000B microscope, equipped
with a digital camera. Mitochondrial fluorescence was measured
in 10–15 random fields per chamber, and data were averaged
per field. For each group, four to six chambers were analyzed.
Experiments with the various compounds were always performed
in parallel with their respective untreated controls. Fluorescence
emission was monitored by using 560 ± 20 nm excitation and
645 ± 37 nm emission filter setting. Data were acquired and
analyzed using Metafluor software (Universal Imaging).
Mitochondrial Membrane Potential and
Complex I Activity
Mitochondrial membrane potential was measured based upon
the accumulation of tetramethylrhodamine methyl ester (TMRM,
Frontiers in Physiology | www.frontiersin.org 3 August 2018 | Volume 9 | Article 1087
fphys-09-01087 August 13, 2018 Time: 17:32 # 4
Vitiello et al. MAO-B Inhibition for DMD Therapy
Molecular Probes) as previously described (Sorato et al., 2014).
Myotubes from DMD patients and healthy donors were obtained
as described above and treated with H2O2 (100 µM) for 30 min
in the absence or presence of safinamide pre-treatment (1 µM,
added 20 min before hydrogen peroxide). Medium was then
replaced with serum-free media supplemented with 25 nM
TMRM for 30 min, and cellular fluorescence images were
acquired with a Leica DMI6000B microscope. Data were acquired
and analyzed using Metafluor software (Universal Imaging).
For detection of fluorescence, 540 ± 20 nm excitation and
590 nm long-pass emission filter settings were used. Clusters of
several mitochondria were identified as regions of interest (ROI),
and fields not containing cells were taken as the background.
To exclude artifacts due to the different loading capacity of
the various cells, which could be erroneously interpreted as
19m differences, sequential digital images were acquired before
and after the addition of carbonyl cyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP, 4 µM), a protonophore that fully
depolarizes mitochondria. 19m was estimated as the difference
in TMRM fluorescence intensity before and after FCCP of
ROI from at least 30 cells. Experiments with the different
agents as described above were always performed in comparison
with untreated cells. Fluorescence values from the latter were
considered as 100%. Complex I activity was measured in myotube
lysates using the specifically designed spectrophotometric assay
described in Spinazzi et al. (2012).
Data Analysis and Statistical Procedures
Data are expressed as the mean ± SEM. Analyses were carried
out using ANOVA ordinary one-way test followed by Tukey’s
multiple comparison test using the Prism software; values with
p< 0.05 were considered significant.
RESULTS
Treatment of mdx Mice With Safinamide
Ameliorates Muscle Pathology
In the first round of in vivo experiments, adult mdx mice
(3-month-old) were subjected to daily intraperitoneal delivery
of safinamide (40 mg/kg/day) for 1 week. At the end of
the treatment, mice were subjected to a set of in vivo force
measurements after electrical stimulation of the sciatic nerve
as described in the M&M section, after which they were
sacrificed to harvest specific muscles for further analyses. Even
though safinamide did not lead to significant improvements
in normalized force (Figure 1A), treated animals showed
a strong and significant reduction in force drop upon
eccentric contractions, a typical hallmark of dystrophic muscles
(Figure 1B). Upon harvesting, gastrocnemius muscles were then
sectioned and subjected to DHE staining to quantify intracellular
ROS. Our findings indicated a significant reduction in the extent
of oxidative stress between treated and control mice (Figure 1C).
A second cohort of mdx mice was then treated for a longer
period, 1 month, and with two different doses of safinamide
(20 and 40 mg/kg/day), with the same administration protocol.
Once again, muscle function was then assessed in vivo in terms
FIGURE 1 | One-week treatment with safinamide rescued functional
alterations and oxidative stress in mdx mice. Three-month-old mdx mice were
treated for 7 days with intra-peritoneal injections of either safinamide
(40 mg/kg/day) or vehicle alone (n = 8 for each condition). Eight syngeneic,
wild-type animals were used as reference. (A) In vivo force–frequency curves
of GC muscles from sham- or safinamide-treated mdx mice showed the
expected drop in normalized force compared to wild type, but no significant
improvement with safinamide. (B) In vivo recordings during eccentric
contractions showed a reduced force drop (measured as percent of initial
force after 20 eccentric contraction in vivo) in safinamide-treated compared to
sham-treated animals. (C) Quantification of DHE fluorescence in
gastrocnemius muscle cryosections from mice treated with vehicle alone
(sham) or with safinamide showed reduced ROS accumulation after
safinamide treatment. (C) Value from wild-type animals was statistically
different from those found in both mdx counterparts; significance bars were
omitted for the sake of chart readability. Data are expressed as mean ± SEM;
∗p < 0.05 and ∗∗p < 0.01.
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FIGURE 2 | One-month treatment with safinamide rescued functional alterations, oxidative stress, and fiber degeneration in mdx mice. Three-month mice were
treated for 30 days with intra-peritoneal injections of either safinamide (20 or 40 mg/kg/day), prednisolone, or vehicle alone (n = 6 for each condition). Eight
syngeneic, wild-type animals were used as reference. (A) Force–frequency curves of gastrocnemius muscles from vehicle-treated or safinamide-treated mice
showed no significant improvement of normalized force in safinamide-treated animals. (B) In vivo recordings during eccentric contractions showed a reduced force
drop (measured as percent of initial force after 20 eccentric contraction in vivo) in safinamide-treated compared to sham-treated animals. (C) Quantification of DHE
fluorescence in gastrocnemius muscle cryosections from sham- and safinamide-treated mice. (D) Oxidation of tropomyosin in gastrocnemius muscles from sham-
and safinamide-treated mice. Y axis reports the amounts of oxidized tropomyosin normalized to that present in sham-treated animals. (E) Quantification of the
necrotic fibers by means of immunohistochemical staining for IgG in gastrocnemius muscle from sham- and safinamide-treated mice. Y axis reports the amounts of
oxidized tropomyosin normalized to that present in sham-treated animals. (F) Quantification of the levels of creatine kinase (CK) in the blood of sham- and
safinamide-treated mice. (A,C–F) values from wild-type animals were always statistically different from those found in all mdx counterparts; significance bars were
omitted for the sake of chart readability. Data are expressed as mean ± SEM; ∗p < 0.05 and ∗∗p < 0.01.
of resistance to eccentric contractions and of normalized force
production. Both safinamide regimens induced a significant
improvement in the resistance against eccentric contractions
(Figure 2A), while no significant improvement in normalized
force could be found in safinamide-treated mdx mice compared
to controls (Figure 2B). In parallel, a set of mdx mice was treated
for the same length of time with the glucocorticoid prednisolone
(i.p., 2 mg/kg/day), the standard treatment for DMD patients
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which is also effective in mice (Keeling et al., 2007 and references
therein). Interestingly, the functional improvement found in
these mice was comparable to that found with safinamide in the
eccentric contraction tests, while the effect on normalized force
reached statistical significance only in prednisolone-treated mice
(Figures 2A,B). DHE staining on gastrocnemius sections were in
agreement with the results of the short-term experiments, as they
confirmed that both safinamide regimens significantly reduced
intracellular ROS (Figure 2C and Supplementary Figure S1). In
addition, in these animals, we measured the levels of tropomyosin
oxidation, in order to verify whether MAO-B-dependent ROS
accumulation could cause oxidative modifications of myofibrillar
proteins. The rationale of this choice relied on our previous
observation that, among myofibrillar proteins, tropomyosin
is particularly susceptible to oxidative stress (Canton et al.,
2006; Menazza et al., 2010). We observed a marked reduction
in oxidation of tropomyosin with both safinamide treatments
(Figure 2D and Supplementary Figure S1). To investigate
whether other pathological features found in dystrophic muscles
had been affected by the 1-month treatment, we then quantified
the number of necrotic fibers present in the gastrocnemius
muscles of treated and control mice by immunofluorescence,
using an anti-murine IgG antibody to label fibers containing
serum immunoglobulin in their sarcoplasm. In this case,
safinamide at 40 mg/kg led to a significant reduction in the
percentage of necrotic fibers (Figure 2E and Supplementary
Figure S2). Since necrosis of muscle fibers leads to a steep
increase in circulating CK, making it a hallmark of Duchenne
dystrophy in humans and in mice, we also compared serum CK
levels between treated and untreated animals. Figure 2F shows
how the treatment with 40 mg/kg safinamide led to an almost
fourfold reduction of CK activity in serum. Finally, we also
performed standard histological evaluations of the sections (by
means of H&E staining), analyzing the percentage of centrally
nucleated fibers and the distribution of fiber diameters, both
indicators of the regenerative status of a striated muscle. No
differences were found between treated and control animals in
either case (Supplementary Figure S2).
Safinamide Reduces Oxidative Stress
and Mitochondrial Dysfunction in Murine
Dystrophic Myoblasts
Next, we isolated myoblasts from mdx and wild-type mice and
proceeded to evaluate their susceptibility to oxidative stress. To
this aim, we used a protocol that we and others had already
exploited to mimic the oxidative stress occurring in several
disease states (Disatnik et al., 1998; Sorato et al., 2014), in
which proliferating myoblasts are exposed to hydrogen peroxide
(100 µM) for 1 h in the presence or in the absence of MAO
inhibitors. The rationale of such treatment is that both muscles
from mdx mice and DMD patients are constantly exposed to high
levels of ROS produced by the infiltrated phagocytic cells (Chen
and Nunez, 2010). Among them, hydrogen peroxide is more
stable and diffuses through membranes. In our experiments, we
tested safinamide at a 1-µM concentration, as well as pargyline,
a strong, first-generation inhibitor of both MAO-A and MAO-
B, at 100 µM. After the challenge with hydrogen peroxide, ROS
levels were assessed by exposing muscle cells to a redox sensitive
fluorescent probe (Mitotracker, CM-H2XRos) and measuring
the corresponding fluorescence emission (Sorato et al., 2014).
Our data show that this protocol greatly increased ROS levels
in mdx but not in wild-type myoblasts and, importantly, such
accumulation was suppressed by treatment with safinamide and
pargyline (Figure 3A and Supplementary Figure S3). The effect
elicited by MAO-B inhibition appears superimposable to that
induced by inhibiting both MAO isoforms. It should be noticed
that no obvious morphological signs of cell death were detected
in any condition with either mdx or wild-type cells (data not
shown), a somewhat expected observation given the combination
of relatively low hydrogen peroxide concentration and short time
of exposure.
FIGURE 3 | MAO-B inhibition reduces ROS accumulation in response to oxidative stress in myoblasts from mdx mice. Myoblasts from mdx and wild-type (wt) mice
were incubated for 1 h with (A) H2O2 (100 µM) or (B) tyramine (Tyr, 100 µM) in the absence or in the presence of 1 µM safinamide or 100 µM pargyline (parg). ROS
levels were assessed by Mitotracker Red CM-H2XRos (MTR, 25 nM). Data expressed as the MTR fluorescence after 1 h from the addition of H2O2 (or Tyr) were
normalized to the values obtained in the absence of stimuli for each sample. Data are the mean ± SEM of three experiments, each using cells originating from
different preps. ∗p < 0.05 and ∗∗p < 0.01.
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Next, we assessed the role of MAO and its activity in
an alternative way, by incubating our murine myoblasts with
tyramine, a typical MAO substrate whose oxidative deamination
generates hydrogen peroxide as a by-product. Once again, higher
levels of ROS were detected in mdx myoblasts as compared with
wild-type cells, and they were blunted by safinamide treatment
(Figure 3B). Finally, it should be noticed that in the absence of
the above-described stressors no significant differences in ROS
levels were observed between mdx and wild-type myoblasts (not
shown).
Safinamide Reduces Oxidative Stress
and Mitochondrial Dysfunction in Human
Dmd Myoblasts and Myotubes
The efficacy of safinamide in reducing ROS formation was then
tested in myoblasts and myotubes obtained from cultured human
myoblasts. Specifically, we used primary cultures derived from
muscle biopsies (one healthy donor and two DMD patients), as
well as immortalized myoblasts (Mamchaoui et al., 2011) (two
healthy donors and two DMD patients, see Table 1 for details).
The rationale of using both primary and immortalized cells
derived from the fact that we wished to rule out the possible effect
of two potentially relevant drawbacks commonly found in the
former, namely a relatively low myogenicity and the unavoidable
presence in the cultures of varying amounts of non-myogenic
cells (Mamchaoui et al., 2011).
Similarly to what had been done with murine cells, human
myogenic cultures were challenged with hydrogen peroxide in
the presence or in the absence of MAO inhibitors. In this
TABLE 1 | Patients’ description.
Age at time of biopsy Type of mutation
DMD 1 (primary cells) 24 months Del ex 44
DMD 2 (primary cells) 24 months Del ex 8–17
DMD 3 (immortalized cells) 20 months Del ex 48–50
DMD 4 (immortalized cells) 20 months Del ex 45–52
case, though, the experiments were performed not only on
cultured myoblasts but also on differentiated myotubes. For
the former, Figure 4A shows how ROS levels increased upon
exposure to hydrogen peroxide in primary DMD myoblasts
and, importantly, that once again they were brought back to
the levels found in non-dystrophic cells by the treatment with
safinamide. Importantly, the hydrogen peroxide challenge did
not affect myoblasts from healthy donors, in accordance with our
present data in murine cells and with our previous data in human
cells (Sorato et al., 2014). The same type of experiment was
then performed on myotubes differentiated from the same cell
preparations. Similarly to myoblasts, upon exposure to hydrogen
peroxide DMD myotubes were found to be more susceptible to
oxidative stress than myotubes from healthy donors and the rise
in ROS levels was prevented by safinamide (Figure 4B).
Next, we investigated whether these findings held true
in cultures comprising only myoblasts, thanks to the use
of the above-mentioned immortalized cell lines. Upon
hydrogen peroxide stimulation, both myoblasts (Figure 5A
and Supplementary Figure S4) and myotubes (Figure 5B
and Supplementary Figure S4) from immortalized DMD cells
displayed increased ROS levels, which were reduced to levels
comparable to those found in controls by the inhibition of
MAO-B. As in primary cultures, hydrogen peroxide challenge
had no effect on the ROS levels found in cells derived from
healthy donors. These finding not only confirmed the increased
susceptibility of DMD cells to oxidative stress but also indicated
that the biological mechanism(s) leading to such phenomenon
were indeed intrinsic to the myogenic cells and did not depend
on the interaction with the non-myogenic fraction of primary
cultures.
Finally, we also assessed the effect of safinamide on
mitochondrial membrane potential, by means of the fluorescent
probe TMRM, after inducing oxidative stress with hydrogen
peroxide. Similarly to what was seen with ROS levels, the
presence of hydrogen peroxide had a marked effect in DMD
myotubes – namely, a reduction in mitochondrial membrane
potential – but not in control cells. Once again, treatment with
safinamide prevented such drop (Figure 6). We hypothesized
FIGURE 4 | MAO-B inhibition decreases ROS accumulation in response to oxidative stress in primary cultured myoblasts and myotubes from DMD patients. Primary
myoblasts (A) or myotubes (B) from one healthy donor (HD 1) and DMD patients (DMD 1 and DMD 2) were loaded with Mitotracker Red CM-H2XRos (MTR, 25 nM).
Oxidative stress was induced by H2O2 addition (100 µM) with or without 1 µM safinamide, as a 20-min pre-treatment. Data expressed as the MTR fluorescence
after 1 h from H2O2 were normalized to the values obtained in the absence of stimuli for each sample. Data are the mean ± SEM of three experiments per cell prep.
∗p < 0.05.
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FIGURE 5 | MAO-B inhibition reduces ROS accumulation in response to H2O2 in immortalized cell lines from DMD patients. Immortalized myoblasts (A) and
myotubes (B) obtained from healthy donors (HD 2 and HD 3) and DMD patients (DMD 3 and DMD 4) were loaded with Mitotracker Red CM-H2XRos as described in
Figure 4. Oxidative stress was induced by H2O2 addition (100 µM) in the absence or presence of 1 µM safinamide or 100 µM pargyline, as a 20 min pre-treatment.
Data expressed as the MTR fluorescence after 1 h from H2O2 were normalized to the values obtained in the absence of stimuli for each sample. Data are the
mean ± SEM of three experiments per cell prep. ∗p < 0.05 and ∗∗p < 0.01.
that the increased levels of ROS in DMD myotubes could affect
mitochondrial membrane potential by decreasing the activity of
the respiratory chain. For this reason, we evaluated the activity
of Complex I in myotubes from a healthy donor and a DMD
patient used for membrane potential determination, but found
no differences between the two (data not shown).
DISCUSSION
Many biological and medical issues related to muscular
dystrophies are far from being conclusively addressed, thus
hampering the development of adequate interventions. The
identification and exploitation of novel pharmacological agents
is, therefore, urgently needed to improve clinical management
of Duchenne patients. The data, we present here, investigate the
mitochondrial enzyme MAO-B as a promising target toward such
goal. In particular, building on our previous findings, the present
study provides two novel aspects: (i) in the context of DMD,
MAO-B plays a key role in determining oxidative stress, and (ii) a
novel inhibitor for this isoform significantly improves functional
impairment occurring in mdx mice and can protect myotubes of
DMD patients from mitochondrial dysfunction.
The first part of our study has been carried out in vivo,
analyzing both force production and histo-pathological features.
For the former, we investigated two parameters: force loss
upon eccentric contractions and normalized force. The rational
of this choice is that one of the main aspects of DMD, as
well as other muscular dystrophies, is the susceptibility of
skeletal muscles to activity-induced muscle damage (Blaauw
et al., 2010; Rader et al., 2016). While the exact molecular
mechanism(s) behind the increased sensitivity to eccentric
contractions is not known, multiple reports have shown that
reducing oxidative stress can be beneficial (Whitehead et al.,
2008). Furthermore, a central role of mitochondria in activity-
dependent increases in pathological oxidative stress has also
been reported in a different kind of myopathy, i.e., central
core disease (Durham et al., 2008). Our data indicate that in
mdx mice the MAO-B-dependent increase in mitochondrial
ROS production plays an important role in decreasing force
production during repeated eccentric contractions. Interestingly,
the positive effect of inhibiting MAO-B could be seen even
after a short (1 week) treatment, suggesting a mechanism that
does not involve extensive tissue remodeling. While specific
experiments will be needed to clarify this point, it is tempting
to hypothesize that the molecular mechanism(s) involved in
the positive effect of safinamide on rescuing activity-induced
force loss are related to an increase in calcium levels within the
mitochondria due to the opening of stretch-dependent calcium
channels (Yeung et al., 2005). As for the normalized force
production, treated animals consistently yield higher values than
controls, but the differences never reached statistical significance,
hence suggesting that ROS levels are not a main player in the
mechanism(s) leading to the decreased isometric force in mdx
muscles, or longer treatment periods are required to induce
significant changes.
Analysis of muscle sections in treated animals confirmed
that safinamide did decrease ROS levels in the fibers of treated
animals as well as the oxidative status of a key component
of the contractile apparatus (tropomyosin), hence providing
new insights on the molecular mechanism(s) linking dystrophin
deficiency to protein oxidation. Under the histopathological
point of view, our data also showed that MAO-B inhibition
provided a significant protection from fiber degeneration, as
demonstrated by the decrease in CK serum levels and by the
lower count of necrotic fibers. These findings suggest that the
end mechanism(s) leading to fiber death are linked, at least
in part, to the excessive production of ROS. On the other
hand, our analyses of fiber size and percentage of central
nuclei did not show any effect of safinamide, thereby suggesting
that, at least in our experimental setting, changes in the levels
of intracellular ROS do not affect the processes of muscle
regeneration. In order to confirm such hypothesis, though,
specific experiments with animals treated with safinamide at a
younger age (i.e., before or during the occurrence of the initial
massive degeneration/regeneration bout) will be needed.
In view of a possible drug repurposing, it is also important to
stress how the functional benefits obtained with safinamide were
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FIGURE 6 | MAO-B inhibition reduces mitochondrial dysfunction in response to H2O2 in myotubes from DMD patients. DMD or HD myotubes (from primary and
immortalized cells) were exposed to H2O2 (100 µM) in the absence or presence of 1 µM safinamide, as a 20 min pre-treatment and then loaded with TMRM (25 nM)
to monitor the mitochondrial membrane potential 19m. (A) Representative kinetics of TMRM fluorescence intensity in one experiment with primary myotubes from
patient DMD2. Single data points are the average of at least 15 individual myotubes. When indicated, FCCP (4 µM) was added to collapse 19m. In the absence of
safinamide, H2O2 treatment caused a drastic drop in the initial membrane potential, which led to a small difference in 19m before and after FCCP. (B–F) Charts
representing the variation in TMRM fluorescence intensities obtained in each condition before and after FCCP; one chart per cell type. Values in Y axis are expressed
as percentage, considering the value in untreated cells as 100%. Each cell type was analyzed in two independent experiments. ∗p < 0.05.
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quite similar to those seen in our animals upon treatment with
prednisolone, one of the glucocorticoids that at present represent
the only standard therapy for Duchenne patients. Such finding is
even more relevant in view of the fact that while glucocorticoids
are usually effective in delaying loss of ambulation (McDonald
et al., 2018), their chronic use present severe side-effects (e.g.,
severe bone demineralization) that in many cases can actually
force discontinuation. On the other hand, the new generation of
MAO-B inhibitors to which safinamide belongs exerts far fewer
unwanted side-effects, not only compared to glucocorticoids
but also to the older, non-specific MAO inhibitors. MAO-
B molecular structure has been identified at high resolution
(Binda et al., 2002, 2004), thus allowing the design of highly
specific inhibitors that have the advantage to avoid the risk of
hypertensive crises that is associated to inhibition of the MAO-A
isoform. Indeed, MAO-B specific inhibitors are currently used in
treatment of several neurological disorders (Youdim et al., 2006).
The involvement of mitochondria in DMD pathogenesis
has been reported both in patients and in animal models, for
instance in terms of deficit of electron transport respiratory
chain components and of enzymes of the tricarboxylic acid
cycle (Timpani et al., 2015). As a downstream consequence,
the ATP levels in these muscles were found to be severely
reduced causing altered ionic homeostasis and oxidative stress
(Rodriguez and Tarnopolsky, 2003; Ramadasan-Nair et al., 2014).
Our in vitro experiments with murine and human myoblast
cultures clearly indicated that cells derived from dystrophic
muscles have a higher susceptibility to oxidative stress compared
to non-dystrophic counterparts. To the best of our knowledge,
this is the first study that explores the source of excess ROS in
myogenic cultures isolated from DMD patients, establishing a
causal relationship between MAO-B-dependent increased ROS
levels and mitochondrial dysfunction.
A remarkable aspect of our findings is that in dystrophic cells
higher sensitivity to oxidative stress appears to be independent
from dystrophin expression, given that in in vitro cultures the
dystrophin gene is expressed in myotubes but not in myoblasts.
This finding is in agreement with previous studies showing
that the impaired metabolism observed in mdx myoblasts was
independent of dystrophin-deficiency (Onopiuk et al., 2009).
In this regard, it should be noticed that recent evidences have
demonstrated the expression of dystrophin in activated satellite
cells, where it plays an important role in establishing their
capability for asymmetric division (Dumont et al., 2015). The
authors also confirmed the absence of dystrophin in proliferating
myoblasts and while they did not investigate the exact timing
and mechanism of disappearance, they showed that already at
72 h after activation of satellite cells dystrophin could be seen
only in a small proportion of them. For these reasons, our
evidences indicate that myoblasts derived from a dystrophic
muscle maintain a series of metabolic alterations even after
prolonged in vitro cultures; the presence of specific epigenetic
markings originated in vivo in the context of dystrophic muscle
seems to be a likely explanation, although specific experiments
will be needed to confirm this hypothesis. In this regard, it
is interesting to notice that Disatnik et al. (1998) reported no
increased sensitivity to oxidative stress in myoblasts cultures
prepared from newborn mdx mice, a developmental stage in
which there is no overt dystrophic phenotype. The use of both
primary and immortalized cells allowed us to demonstrate that
the molecular mechanisms leading to the peak of oxidative stress
present in DMD cells take place specifically within myoblasts.
By the same token, the fact that in our assays immortalized
cells showed the same phenotype found in primary cultures
further confirms that the former are a reliable alternative to the
latter, while presenting clear advantages in terms of long-term
availability and reproducibility.
At present, our findings do not provide indications about
the mechanisms linking MAO-mediated oxidative stress to
mitochondrial depolarization. As a preliminary attempt, we
verified whether the accumulation of ROS in DMD myotubes
affected the activity of NADH dehydrogenase, the complex of
the respiratory chain that is more susceptible to oxidative stress,
but found no differences between healthy donor and DMD cells.
Further studies will be aimed at characterizing the molecular
targets of MAOB-dependent ROS increased levels.
Overall, these results provide clear evidence of safinamide
efficacy in reducing oxidative stress in dystrophic skeletal
muscle. Importantly, though, safinamide treatment should not
be considered just another case of antioxidant therapy, as it
does not act as a general ROS scavenger. Such an approach
could actually be cause of some concerns, considering that small
amounts of ROS are required for intracellular signaling. On the
contrary, safinamide act by specifically preventing the formation
of a subset of mitochondrial ROS that becomes disproportionate
in pathological conditions because of MAO over activation.
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